Recursion Pharmaceuticals, Inc. (RXRX)

8.35 +0.30 (+3.73%) 收市：04:00PM EDT

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203
https://www.recursion.com

版塊: Healthcare
行業: Biotechnology
全職員工: 500

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Christopher C. Gibson Ph.D.	Co-Founder, CEO & Director	806.72k	2.18M	1983
Ms. Tina Marriott Larson	COO & President	702.24k	397.61k	1975
Dr. Blake C. Borgeson Ph.D.	Co-Founder & Director	40k	無	1982
Dr. Michael Secora Ph.D.	Chief Financial Officer	629.78k	3.62M	1983
Dr. David J. Mauro M.D., Ph.D.	Chief Medical Officer	674.74k	無	1965
Kevin Leggat	Vice President of Finance & Accounting	無	無	無
Mr. Benjamin Mabey M.S.	Chief Technology Officer	無	無	1983
Mr. Jared Allenbach	Senior Director of Investor Relations	無	無	無
Mr. Nathan Hatfield	Chief Legal Officer & General Counsel	無	無	無
Mr. Ryan Kelly	Chief Communications Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

公司管治

截至 2024年7月1日 止，Recursion Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：3；董事會：6；股東權利：10；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。